> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-17/
- Published: 2020-09-20T12:00:00.000Z
- Updated: 2026-09-14T16:29:19.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147182

[**Consumer Organizations Sought for Advisory Panel Selections**](https://www.fdaweb.com/consumer-organizations-sought-for-advisory-panel-selections/)  
*Federal Register* notice: FDA seeks consumer organizations interested in participating in selecting voting or nonvoting consumer representatives to serve on its advisory committees or panels. 09/18/2020

[**Info Collection on Social Behavioral Sciences Data**](https://www.fdaweb.com/info-collection-on-social-behavioral-sciences-data/)  
*Federal Register* notice: FDA seeks comments on a new information collection for data to support cross-center collaboration for social behavioral sciences associated with disease prevention and treatment. 09/18/2020

[**New Study on Disclosures in Drug Ads**](https://www.fdaweb.com/new-study-on-disclosures-in-drug-ads/)  
*Federal Register* notice: FDA seeks comments on a new information collection entitled “Examination of Secondary Claim Disclosures and Biosimilar Disclosures in Prescription Drug Promotional Materials.” 09/17/2020

[**Stakeholder Participation for Drug User Fee Reauthorization**](https://www.fdaweb.com/stakeholder-participation-for-drug-user-fee-reauthorization/)  
*Federal Register* notice: FDA seeks patient and consumer advocacy groups, healthcare professionals, and scientific and academic experts to participate in periodic consultation meetings on reauthorizing the Prescription Drug User Fee Act. 09/17/2020

[**Info Collection on Opioid Abuse Deterrent Formulations**](https://www.fdaweb.com/info-collection-on-opioid-abuse-deterrent-formulations/)  
*Federal Register* notice: FDA sends to OMB a new information collection entitled “Health Care Providers’ Understanding of Opioid Analgesic Abuse Deterrent Formulations (ADF).” 09/16/2020

[**Study of Multiple Indications in DTC Ads**](https://www.fdaweb.com/study-of-multiple-indications-in-dtc-ads/)  
*Federal Register* notice: FDA seeks comments on a proposed information collection entitled “Study of Multiple Indications in Direct-to-Consumer Television Advertisements.” 09/15/2020

[**Survey on Physician Perceptions of Boxed Warnings**](https://www.fdaweb.com/survey-on-physician-perceptions-of-boxed-warnings/)  
*Federal Register* notice: FDA sends to OMB a proposed information collection entitled “Healthcare Provider Perception of Boxed Warning Information Survey.” 09/15/2020